Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus PYROLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus PYROLITE.
MACROTEC vs PYROLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Pyrolite is not a recognized pharmaceutical drug. No mechanism of action data available.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
1000 mg orally every 8 hours for 7 days.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal half-life: 4.5 hours (range 3.8–5.2). Clinical context: Eliminated rapidly; no accumulation with q6h dosing; dose adjustment needed in CrCl <30 mL/min.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Renal: 70% unchanged; Fecal: 20% as metabolites; Biliary: 10% as conjugates.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical